-
Security Type
-
Non-Voting Equity
-
Categories
-
Technology
-
Min Investment
-
$228
-
Offering Date
-
January 07, 2022
-
Expected Close Date
-
June 29, 2022
-
Target Raise
-
$10.00K-$1.07M
-
No. Investors
-
84
-
Security Price
-
$2.85
-
Valuation
-
$89,300,000
- Number of Employees
- 10
- Cash
- $73,150
- Revenue
- $0
- Short Term Debt
- $385,680
- Cost of Goods
- $0
- Long Term Debt
- $25,050
- Net Income
- $-728,230
Company Description
Scinovia’s mission is to produce state-of-the-art diagnostics to help doctors make more data-driven decisions during procedures to save more lives. Scinovia developed VUFLOW, the future of non-contact imaging diagnostics for blood flow during surgery.
Perks
StartEngine OWNERS Exclusive Click here to learn more
$498+ Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$1,500+ Investment
$1,500+ Tier
Invest $1,500+ and receive 15% bonus shares
$5,000+ Investment
$5,000+ Tier
Invest $5,000+ and receive 20% bonus shares
$25,000+ Investment
$25,000+ Tier
Invest $25,000+ and receive 25% bonus shares
$50,000+ Investment
$50,000+ Tier
Invest $50,000+ and receive 30% bonus shares
$100,000+ Investment
$100,000+ Tier
Invest $100,000+ and receive 40% bonus shares
Key Deal Facts
Save more lives: A big challenge many surgeons face is knowing if procedures have optimal blood flow for quick recovery.
Disrupt a $500M market: Displace legacy contact probe* and dye* methods over past 60 years with VUFLOW, one of the first non-contact measurement device to visualize blood flow speeds in surface vessels during major surgeries.
Platform Technology: VUFLOW may be applicable to many types of surgeries. There are over 300M per year. Initial markets are heart bypass and organ transplants.